A Study on the Lipid Lowering Effect of Coenzyme Q 10 in Dyslipidaemic Patients who Underwent Percutaneous Transluminal Coronary Angioplasty and receive Atorvastatin Therapy
The trial was conducted to study the lipid lowering effect of Coenzyme Q 10. It was a randomized controlled trial. Patients who underwent PTCA and receiving atorvastatin therapy were enrolled for the study. Totally 104 patients were enrolled. All the patients enrolled for the study were divided in to two groups at random and categorized as Group 1 and Group 2. The baseline serum lipid profile was measured for all the 104 patients and documented on the patient data sheet. Then Group 1 was given Atorvastatin 40 mg/day as they were already taking that along with drugs for diabetes and/or hypertension. Group 2 patients additionally received Coenzyme Q 10 30 mg/day orally. Both the groups of patients were monitored for compliance, and for ADRs and side effects. At the end of 3 months the lipid profile of the patients were measured again as the end point. Then the lipid profiles of Group 1 were compared with those of Group 2. The results showed that the percentage reduction in serum total cholesterol, LDL, VLDL and Triglycerides, were much higher in Group 2, compared to Group 1. The percentage increase in serum HDL level was much higher in Group 2, compared to Group 1. The study gives a strong evidence for the lipid lowering action of Coenzyme Q 10.